Pareto and Analysguiden publish research reports with SEK 25 per share price targets and ExpreS2ion publishes third quarter financial report video presentation
Hørsholm, Denmark, November 18, 2022 – ExpreS2ion Biotech Holding AB’s affiliate ExpreS2ion Biotechnologies ApS (“ExpreS2ion") announces that Pareto Securities and Analysguiden have both published research reports on ExpreS2ion in November. Pareto reiterated its SEK 25 price target while Analysguiden reduced its price target to SEK 25 per share from SEK 30 per share. Furthermore, a filmed company presentation by CEO Bent U. Frandsen and CFO Keith Alexander, hosted by H.C. Andersen Capital, in which they provide an update on ExpreS2ion’s powerful technology platform for vaccine development,